laurolitsine has been researched along with adenosine diphosphate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, YL; Hsueh, CM; Ko, FN; Lee, SS; Liu, KC; Teng, CM | 1 |
| Chongming, W; Lin, D; Ning, M; Ruiqi, W; Weiying, L; Xiaopo, Z; Yanan, Y; Yinfeng, T; Yiying, L; Yong, Z; Zhi, Z | 1 |
2 other study(ies) available for laurolitsine and adenosine diphosphate
| Article | Year |
|---|---|
Antiplatelet effects of some aporphine and phenanthrene alkaloids in rabbits and man.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adenosine Triphosphate; Animals; Aporphines; Arachidonic Acid; Blood Platelets; Collagen; Cyclic AMP; Guaiacol; Humans; Isoquinolines; Isotope Labeling; Lipoxygenase Inhibitors; Male; Phenanthrenes; Platelet Activating Factor; Platelet Aggregation Inhibitors; Quinolines; Rabbits; Radioimmunoassay; Structure-Activity Relationship; Thrombin; Thromboxane B2; Vasoconstrictor Agents | 1997 |
Laurolitsine ameliorates type 2 diabetes by regulating the hepatic LKB1-AMPK pathway and gut microbiota.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Aporphines; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Glucose; Hypoglycemic Agents; Lactic Acid; Liver; Mice; Mice, Inbred C57BL | 2022 |